Predictors of severe outcomes associated with C lostridium difficile infection in patients with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 7, 2012, Pages 789-795

  Ananthakrishnan, A N ^a,b   Guzman Perez, R ^c   Gainer, V ^c   Cai, T ^d   Churchill, S ^e   Kohane, I ^b,e   Plenge, R M ^f   Murphy, S ^c,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Informatics   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e I2b2 National Center for Biomedical Computing   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINOSALICYLIC ACID; C REACTIVE PROTEIN; CREATININE; HEMOGLOBIN; IMMUNOMODULATING AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD CHEMISTRY; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; ENTERITIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SCORING SYSTEM; SENSITIVITY ANALYSIS; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; COLECTOMY; CREATININE; FEMALE; HEMOGLOBINS; HOSPITALIZATION; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; SERUM ALBUMIN; TIME FACTORS; YOUNG ADULT;

EID: 84858284133     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05022.x     Document Type: Article

References (36)

1. Ananthakrishnan AN,. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011; 8: 17-26.
2. O'Donoghue C, Kyne L,. Update on Clostridium difficile infection. Curr Opin Gastroenterol 2011; 27: 38-47.
3. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466-72. (Pubitemid 39179608)
4. Rupnik M, Wilcox MH, Gerding DN,. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7: 526-36.
5. Dubberke ER, Wertheimer AI,. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 2009; 30: 57-66.
6. Pituch H,. Clostridium difficile is no longer just a nosocomial infection or an infection of adults. Int J Antimicrob Agents 2009; 33 (Suppl. 1): S42-5.
7. Nguyen GC, Kaplan GG, Harris ML, Brant SR,. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 1443-50. (Pubitemid 351813903)
8. Ananthakrishnan AN, McGinley EL, Binion DG,. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008; 57: 205-10. (Pubitemid 351158048)
9. Jen MH, Saxena S, Bottle A, Aylin P, Pollok RC,. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 1322-31.
10. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 345-51. (Pubitemid 46401531)
11. Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD,. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 339-44. (Pubitemid 46401530)
12. Goodhand JR, Alazawi W, Rampton DS,. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 428-41.
13. Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG,. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 976-83.
14. Jodorkovsky D, Young Y, Abreu MT,. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci 2010; 55: 415-20.
15. Ananthakrishnan AN, Issa M, Binion DG,. Clostridium difficile and inflammatory bowel disease. Gastroenterol Clin North Am 2009; 38: 711-28.
16. Chiplunker A, Ananthakrishnan AN, Beaulieu DB, et al. Long-term impact of Clostridium difficile on inflammatory bowel disease. Gastroenterology 2009; 136 (Suppl. 1): S1145.
17. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2000; 31: 431-55.
18. Fekety R,. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997; 92: 739-50.
19. Fekety R, Shah AB,. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993; 269: 71-5. (Pubitemid 23006526)
20. Aslam S, Hamill RJ, Musher DM,. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005; 5: 549-57. (Pubitemid 41196754)
21. Bartlett JG,. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008; 46 (Suppl. 1): S4-11. (Pubitemid 351323660)
22. Kelly CP,. A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. difficile infection. JAMA 2009; 301: 954-62.
23. McFarland LV,. Renewed interest in a difficult disease: Clostridium difficile infections-epidemiology and current treatment strategies. Curr Opin Gastroenterol 2009; 25: 24-35.
24. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB,. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-7. (Pubitemid 47101025)
25. Libot A, Issa M, Zadvornova Y, et al. Initial Vancomycin Monotherapy is Associated With Higher Rates of Subsequent Clostridium difficile Infection in Inflammatory Bowel Disease Population. Digestive Disease Week, Chicago, IL. 2011: Abstract # 992.
26. Elixhauser A, Steiner C, Harris DR, Coffey RM,. Comorbidity measures for use with administrative data. Med Care 1998; 36: 8-27. (Pubitemid 128456396)
27. Kumar S, Ghoshal UC, Aggarwal R, Saraswat VA, Choudhuri G,. Severe ulcerative colitis: prospective study of parameters determining outcome. J Gastroenterol Hepatol 2004; 19: 1247-52. (Pubitemid 39481757)
28. Lungulescu OA, Cao W, Gatskevich E, Tlhabano L, Stratidis JG,. CSI: a severity index for Clostridium difficile infection at the time of admission. J Hosp Infec 2000; 79: 151-4.
29. Gujja D, Friedenberg FK,. Predictors of serious complications due to Clostridium difficile infection. Aliment Pharmacol Ther 2009; 29: 635-42.
30. Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K,. A simple risk score to identify colectomy risk in ulcerative colitis hospitalizations. Inflamm Bowel Dis 2010; 16: 1532-40.
31. Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007; 26: 411-9. (Pubitemid 47063146)
32. Truelove SC, Witts LJ,. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041-8.
33. Daperno M, Sostegni R, Rocca R, et al. Review article: medical treatment of severe ulcerative colitis. Aliment Pharmacol Ther 2002; 16 (Suppl. 4): 7-12.
34. Ben-Horin S, Margalit M, Bossuyt P, et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection. Clin Gastroenterol Hepatol 2009; 7: 981-7.
35. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Me 2011; 364: 422-31.
36. Dubberke ER, Reske KA, McDonald LC, Fraser VJ,. ICD-9 codes and surveillance for Clostridium difficile-associated disease. Emerg Infect Dis 2006; 12: 1576-9. (Pubitemid 44570903)